Y Intercept Hong Kong Ltd Has $1.27 Million Stake in Bristol Myers Squibb Company $BMY

Y Intercept Hong Kong Ltd reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 85.9% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 28,055 shares of the biopharmaceutical company’s stock after selling 170,707 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Bristol Myers Squibb were worth $1,265,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of BMY. CVA Family Office LLC increased its holdings in Bristol Myers Squibb by 2.6% in the third quarter. CVA Family Office LLC now owns 8,959 shares of the biopharmaceutical company’s stock valued at $404,000 after purchasing an additional 223 shares during the last quarter. Richwood Investment Advisors LLC increased its stake in shares of Bristol Myers Squibb by 1.7% in the 2nd quarter. Richwood Investment Advisors LLC now owns 13,303 shares of the biopharmaceutical company’s stock valued at $616,000 after acquiring an additional 225 shares during the last quarter. Mccarter Private Wealth Services LLC boosted its stake in Bristol Myers Squibb by 5.0% during the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock worth $222,000 after acquiring an additional 235 shares during the last quarter. Creative Financial Designs Inc. ADV grew its holdings in Bristol Myers Squibb by 26.7% during the second quarter. Creative Financial Designs Inc. ADV now owns 1,123 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 237 shares during the period. Finally, Center for Financial Planning Inc. increased its stake in Bristol Myers Squibb by 15.9% in the second quarter. Center for Financial Planning Inc. now owns 1,869 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 256 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 1.4%

NYSE:BMY opened at $55.03 on Friday. The company has a market cap of $112.02 billion, a P/E ratio of 18.59, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The business has a 50 day moving average price of $53.41 and a two-hundred day moving average price of $48.66. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.80 earnings per share. As a group, analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be paid a dividend of $0.63 per share. The ex-dividend date is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 85.14%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BMY shares. Citigroup reissued a “neutral” rating and issued a $60.00 price target (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Tuesday. Scotiabank restated a “sector perform” rating and issued a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Piper Sandler reaffirmed an “overweight” rating and set a $66.00 price target (up previously from $62.00) on shares of Bristol Myers Squibb in a research report on Wednesday. Cantor Fitzgerald reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Finally, Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their target price for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Seven investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $57.43.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.